Malignancy of Hepatobiliary System or Pancreas with MCC DRG Reimbursement

DRG 435 addresses malignancy of the hepatobiliary system or pancreas with a Major Complication or Comorbidity, covering complex oncologic admissions with significant resource needs. It matters for inpatient reimbursement because the Major Complication or Comorbidity designation increases the Diagnosis-Related Group weight and thus the Medicare payment for high-acuity cases.

DRG 435 Overview

DRG 435 covers hospital admissions for malignant neoplasms of the hepatobiliary system or pancreas when a Major Complication or Comorbidity is present. Typical cases include advanced or complicated tumors requiring major procedures, intensive postoperative care, or management of severe systemic complications. This Diagnosis-Related Group influences Medicare payment by grouping resource use for high-acuity oncologic and hepatobiliary care into a single inpatient reimbursement category. Accurate coding of diagnoses and complications is critical because the presence of a Major Complication or Comorbidity affects payment weighting.

DRG 435 Overview

Perioperative and neoadjuvant therapy trials assessing timing and sequencing of systemic chemotherapy and/or radiotherapy in resectable or borderline-resectable hepatobiliary and pancreatic cancers. These studies enroll patients with localized disease who are undergoing major hepatic, biliary, or pancreatic resection and evaluate endpoints such as margin-negative (R0) resection rates, tumor downstaging, perioperative morbidity, and short-term mortality; they are relevant because optimizing preoperative therapy can reduce in-hospital complications, length of stay, and readmissions that drive inpatient costs. Providers and payers benefit from evidence about which preoperative approaches improve surgical candidacy and resource utilization without increasing severe treatment-related complications.
Comparative effectiveness and safety studies of multimodal inpatient management strategies for advanced or metastatic hepatobiliary and pancreatic malignancies with major complications (e.g., biliary obstruction, cholangitis, hemorrhage, or tumor-related liver failure). These trials compare interventions such as endobiliary stenting approaches, palliative biliary decompression techniques, interventional radiology procedures, and inpatient symptom-control protocols in patients admitted with acute complications, measuring outcomes like resolution of infection, need for repeat procedures, ICU transfer, and in-hospital mortality. This research directly informs clinicians and payers about which acute-care pathways reduce length of stay, intensive-resource use, and avoidable costly complications in a high-MCC population characteristic of DRG 435.
Post-discharge outcomes and care-coordination studies focused on readmission reduction, transition-of-care models, and palliative care integration for patients discharged after hospitalization for hepatobiliary or pancreatic malignancy with major complications. These pragmatic trials enroll high-risk discharged patients to compare structured follow-up interventions (nurse navigator programs, early outpatient clinic access, home health coordination) versus usual care, examining 30- and 90-day readmissions, emergency visits, symptom burden, and downstream inpatient costs. Results are highly relevant to hospitals and payers because reducing preventable readmissions and aligning care with patient goals can materially lower recurrent inpatient utilization and improve quality metrics for this complex DRG population.

Perioperative and neoadjuvant therapy trials assessing timing and sequencing of systemic chemotherapy and/or radiotherapy in resectable or borderline-resectable hepatobiliary and pancreatic cancers. These studies enroll patients with localized disease who are undergoing major hepatic, biliary, or pancreatic resection and evaluate endpoints such as margin-negative (R0) resection rates, tumor downstaging, perioperative morbidity, and short-term mortality; they are relevant because optimizing preoperative therapy can reduce in-hospital complications, length of stay, and readmissions that drive inpatient costs. Providers and payers benefit from evidence about which preoperative approaches improve surgical candidacy and resource utilization without increasing severe treatment-related complications.
Comparative effectiveness and safety studies of multimodal inpatient management strategies for advanced or metastatic hepatobiliary and pancreatic malignancies with major complications (e.g., biliary obstruction, cholangitis, hemorrhage, or tumor-related liver failure). These trials compare interventions such as endobiliary stenting approaches, palliative biliary decompression techniques, interventional radiology procedures, and inpatient symptom-control protocols in patients admitted with acute complications, measuring outcomes like resolution of infection, need for repeat procedures, ICU transfer, and in-hospital mortality. This research directly informs clinicians and payers about which acute-care pathways reduce length of stay, intensive-resource use, and avoidable costly complications in a high-MCC population characteristic of DRG 435.
Post-discharge outcomes and care-coordination studies focused on readmission reduction, transition-of-care models, and palliative care integration for patients discharged after hospitalization for hepatobiliary or pancreatic malignancy with major complications. These pragmatic trials enroll high-risk discharged patients to compare structured follow-up interventions (nurse navigator programs, early outpatient clinic access, home health coordination) versus usual care, examining 30- and 90-day readmissions, emergency visits, symptom burden, and downstream inpatient costs. Results are highly relevant to hospitals and payers because reducing preventable readmissions and aligning care with patient goals can materially lower recurrent inpatient utilization and improve quality metrics for this complex DRG population.

OpenPayer

Malignancy of Hepatobiliary System or Pancreas with MCC: Inpatient Reimbursement Overview

Sign up for drg 435 policy alerts

DRG 435 Overview

OpenPayer

Malignancy of Hepatobiliary System or Pancreas with MCC: Inpatient Reimbursement Overview

Sign up for drg 435 policy alerts

DRG 435 Overview

Clinical Trials

Related Codes

References

Clinical Trials

Related Codes

References